Fight CRC Clinical Trial Finder
| NCT ID | Title | 阶段 | Date Added | 地点 | Prior IO Allowed | CRC-directed | Status | 药物 | 标签 |
|---|---|---|---|---|---|---|---|---|---|
| NCT ID NCT03994601 |
TitleBMS-986288单独或与Nivolumab联合治疗晚期实体瘤的免疫疗法研究 | 阶段
第 1 阶段
|
Date Added 2019-06-21 |
地点
California, United States
Colorado, United States Maryland, United States Missouri, United States New Jersey, United States 阿根廷 加拿大 智利 法国 意大利 西班牙 |
Prior IO Allowed 是 |
CRC-directed 没有 |
Status
活跃，非招募
|
药物
BMS-986288, Nivolumab, Opdivo |
标签
MSI-H/ MMRd, MSS/ MMRp
|
| NCT ID NCT03970382 |
TitleA Study of Gene Edited Autologous Neoantigen Targeted TCR T Cells With or Without Anti-PD-1 in Patients With Solid Tumors | 阶段
第 1 阶段
|
Date Added 2019-05-31 |
地点
California, United States
Illinois, United States New York, United States Tennessee, United States Washington, United States |
Prior IO Allowed 是 |
CRC-directed 是 |
Status
暂停
|
药物
IL-2, NeoTCR-P1 adoptive cell therapy, Nivolumab |
标签
MSS/ MMRp
|
| NCT ID NCT03983993 |
TitleNiraparib and Panitumumab in Patients With Advanced or Metastatic Colorectal Cancer | 阶段
第二阶段
|
Date Added 2019-06-12 |
地点
Georgia, United States
|
Prior IO Allowed 是 |
CRC-directed 是 |
Status
活跃，非招募
|
药物
Niraparib, panitumumab, Vectibix, Zejula |
标签
MSS/ MMRp
|
| NCT ID NCT03745326 |
Title给 HLA-A*11:01 患者注射用识别变异 RAS G12D 变异的小鼠 T 细胞受体转导的外周血淋巴细胞 | 阶段
Phase 1, Phase 2
|
Date Added 2018-11-19 |
地点
Maryland, United States
|
Prior IO Allowed 是 |
CRC-directed 是 |
Status
招聘
|
药物
Aldesleukin, anti-KRAS G12D mTCR PBL, Cyclophosphamide, Fludarabine |
标签
MSI-H/ MMRd, MSS/ MMRp
|
| NCT ID NCT03280511 |
Title对切除的高危结肠癌患者进行辅助加压腹腔内气溶胶化疗 (PIPAC) | 阶段
第二阶段
|
Date Added 2017-09-12 |
地点
丹麦
|
Prior IO Allowed 是 |
CRC-directed 是 |
Status
招聘
|
药物
PIPAC |
标签
MSI-H/ MMRd, MSS/ MMRp
|
| NCT ID NCT05141474 |
Title评估体外下一代新抗原选择的肿瘤浸润淋巴细胞（TIL）疗法在晚期上皮肿瘤和免疫检查点阻断剂（ICB）耐受性实体瘤中的安全性和耐受性 | 阶段
早期阶段 1
|
Date Added 2021-12-02 |
地点
西班牙
|
Prior IO Allowed 是 |
CRC-directed 没有 |
Status
招聘
|
药物
Interleukin-2, NEXTGEN-TIL, Non-myeloablative Lymphodepletion (NMA-LD) Regimen |
标签
MSI-H/ MMRd, MSS/ MMRp
|
| NCT ID NCT05215574 |
Title晚期或转移性实体瘤 NGM831 单药及与 Pembrolizumab 联合用药研究 | 阶段
第 1 阶段
|
Date Added 2022-01-31 |
地点
Arizona, United States
California, United States Florida, United States Michigan, United States New York, United States Oklahoma, United States Texas, United States |
Prior IO Allowed 是 |
CRC-directed 是 |
Status
活跃，非招募
|
药物
NGM831, NGM831 plus pembrolizumab |
标签
MSI-H/ MMRd, MSS/ MMRp
|
| NCT ID NCT04332653 |
TitleNT-I7 (Efineptakin Alfa) in Combination With Pembrolizumab in Participants With Advanced Solid Tumors | 阶段
第 1 阶段
|
Date Added 2020-04-03 |
地点
Florida, United States
Michigan, United States Missouri, United States North Carolina, United States Pennsylvania, United States Tennessee, United States Texas, United States |
Prior IO Allowed 是 |
CRC-directed 是 |
Status
活跃，非招募
|
药物
NT-I7, Pembrolizumab |
标签
MSS/ MMRp
|
| NCT ID NCT03851614 |
TitleBasket Combination Study of Inhibitors of DNA Damage Response, Angiogenesis and Programmed Death Ligand 1 in Patients With Advanced Solid Tumors | 阶段
第二阶段
|
Date Added 2019-02-22 |
地点
加拿大
|
Prior IO Allowed 是 |
CRC-directed 是 |
Status
活跃，非招募
|
药物
Cediranib, durvalumab, Olaparib |
标签
MSS/ MMRp
|
| NCT ID NCT03832855 |
Title评估 pING-hHER3FL 的免疫原性 | 阶段
第 1 阶段
|
Date Added 2019-02-06 |
地点
North Carolina, United States
|
Prior IO Allowed 是 |
CRC-directed 没有 |
Status
招聘
|
药物
pING-hHER3FL |
标签
MSI-H/ MMRd, MSS/ MMRp
|
